HAEM5:T-prolymphocytic leukaemia: Difference between revisions

[unchecked revision]

← Older edit Newer edit →

VisualWikitext

@@ Line 68: / Line 68: @@
 |Positive (universal)||cyTCL1(highest specificity), CD2, CD3 (may be weak), CD5, CD7 (strong), TCR-α/β
 |-
 |Positive (subset)||CD4 (in some cases CD4+/CD8+ or CD4-/CD8+), CD52, activation markers are variable (CD25, CD38, CD43, CD26, CD27)
 |-
 |Negative (universal)||TdT, CD1a, CD57, CD16
@@ Line 214: / Line 214: @@
 |
 |-
-|''TCL1A''
+|ATM
-|Oncogene
+|TSG
 |
 |ATM mutations
@@ Line 254: / Line 254: @@
 |
 |-
-|''JAK1, JAK3, STAT5b, IL2RG''
+|''JAK1, JAK3, STAT5B''
-|
+|Oncogene
-|
-|
-|
-|
-|
-|
-|
-|-
-|''JAK1''
-|
-|20% (COSMIC)
-<span class="blue-text">EXAMPLE:</span> 30% (add Reference)
-|
-|
-|
-|
-|
-|
-|-
-|''JAK3''
-|
 |
 |
@@ Line 286: / Line 264: @@
 |
 |-
-|''STAT5B''
+|''IL2RG''
 |
 |
@@ Line 304: / Line 282: @@
 !Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome
 |-
-|TCL1A
+|''TCL1A rearrangement''
-|AKT signaling and TCR signal amplification pathways
+|''AKT'' signaling and TCR signal amplification pathways
+|Increased cell survival and proliferation
+|-
+|''MTCP1''
+|''AKT'' signaling and TCR signal amplification pathways
 |Increased cell survival and proliferation
 |-
-|''JAK1, JAK3, STAT5b, IL2RG''
+|''ATM, CHEK2''
-|JAk-STAT pathway
+|DNA damage repair pathway
-|<span class="blue-text">EXAMPLE:</span> Abnormal gene expression program
+|Genomic instability
+|-
+|''JAK1, JAK3, STAT5B''
+|''JAK-STAT'' pathway
+|Unchecked cell growth and survival
+|-
+|''IL2RG''
+|Cytokine signaling
+|Promoting lymphocyte proliferation
+|-
+|''EZH2''
+|Transcription regulator
+|Altering the epigenetic landscape
 |}
 ==Genetic Diagnostic Testing Methods==